Baidu
map

JAMA子刊:抗逆转录病毒治疗后卡波西肉瘤继发癌的变化

2017-09-04 xuyihan MedSci原创

20世纪80年代和90年初进行的研究表明患有卡波西肉瘤(KS)人患其他癌症的风险更高。感染了人类免疫缺陷病毒(HIV)/AIDS和KS的流行病学已发生了变化,患有HIV/AIDS和KS的患者现在活得更长。而近日在JAMA上发表的一篇文章则研究了近年来KS患者中继发癌症的发展趋势,并评估了不同时期KS后继发癌症的风险。

20世纪80年代和90年初进行的研究表明患有卡波西肉瘤(KS)人患其他癌症的风险更高。感染了人类免疫缺陷病毒(HIV)/AIDS和KS的流行病学已发生了变化,患有HIV/AIDS和KS的患者现在活得更长。而近日在JAMA上发表的一篇文章则研究了近年来KS患者中继发癌症的发展趋势,并评估了不同时期KS后继发癌症的风险。

该研究利用了检测、流行病学和最终结果(SEER)数据库中9个癌症登记处的纵向数据来确定1973年1月至2013年12月确诊的KS病例。主要结果是KS患者继发癌的发生。只有经诊断为KS后2个月后才考虑继发癌。计算了在前-AIDS时代(1973-1979)、前-高效抗逆转录病毒治疗(HAART)时代(1980-1995)和HAATR时代(1996-2013)标准化发病率(SIRs)。然后对1996年-2013年诊断的病例以诊断年龄(<65岁和≥65年)、KS和继发肿瘤之间的潜伏期(1年、2-5年、>5-10年和>10年)及高或低登记报告的HIV/AIDS率进行了子集的层状分析。

研究结果表明在诊断为KS的14905例患者中,13721(92.1%)例在诊断时年龄小于65岁,14356(96.3%)例为男性。从1980到1995年,SIRs对直肠肿瘤为2.01(95% CI,1.00-3.60)、肛门癌症为49.70(95% CI,33.53-70.94)、肝癌症为4.98(95% CI,2.79-8.22)、宫颈癌为13.7(95% CI,2.82-40.03)、霍奇金淋巴瘤为6.4(95% CI,2.76-12.60)和4非霍奇金淋巴瘤为48.97(95% CI,44.85-53.36)。从1996年到2013年,肛门癌、霍奇金淋巴瘤、非霍奇金淋巴瘤和肝癌仍然与KS有关,以下有显着的SIRs增加:舌癌6.99(95% CI,3.20-13.27)、阴茎癌10.28(95% CI,1.24-37.13)和急性淋巴细胞白血病17.62(95% CI,3.63-51.49)。KS后继发肿瘤的SIR前-HAART到HAART时代从3,36下降到了1.94。

由上述研究可见KS后继发癌症的总风险率显着下降。某些癌症,包括急性淋巴细胞白血病、舌癌和阴茎癌,在HAART时代比前-HAART时代变得更普遍。在KS患者中,密切监测和筛查这些继发癌症是必要的。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053188, encodeId=9a7420531882c, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat May 12 03:57:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926848, encodeId=35d71926848d2, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Mon Jun 11 04:57:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688290, encodeId=c1f9168829076, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Mon Apr 02 21:57:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747265, encodeId=34f01e4726537, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 17 23:57:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724441, encodeId=ebc41e2444183, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Sep 15 20:57:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554357, encodeId=5b39155435e20, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Wed Sep 06 02:57:00 CST 2017, time=2017-09-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053188, encodeId=9a7420531882c, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat May 12 03:57:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926848, encodeId=35d71926848d2, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Mon Jun 11 04:57:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688290, encodeId=c1f9168829076, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Mon Apr 02 21:57:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747265, encodeId=34f01e4726537, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 17 23:57:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724441, encodeId=ebc41e2444183, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Sep 15 20:57:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554357, encodeId=5b39155435e20, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Wed Sep 06 02:57:00 CST 2017, time=2017-09-06, status=1, ipAttribution=)]
    2018-06-11 hxj0117
  3. [GetPortalCommentsPageByObjectIdResponse(id=2053188, encodeId=9a7420531882c, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat May 12 03:57:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926848, encodeId=35d71926848d2, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Mon Jun 11 04:57:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688290, encodeId=c1f9168829076, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Mon Apr 02 21:57:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747265, encodeId=34f01e4726537, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 17 23:57:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724441, encodeId=ebc41e2444183, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Sep 15 20:57:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554357, encodeId=5b39155435e20, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Wed Sep 06 02:57:00 CST 2017, time=2017-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2053188, encodeId=9a7420531882c, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat May 12 03:57:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926848, encodeId=35d71926848d2, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Mon Jun 11 04:57:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688290, encodeId=c1f9168829076, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Mon Apr 02 21:57:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747265, encodeId=34f01e4726537, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 17 23:57:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724441, encodeId=ebc41e2444183, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Sep 15 20:57:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554357, encodeId=5b39155435e20, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Wed Sep 06 02:57:00 CST 2017, time=2017-09-06, status=1, ipAttribution=)]
    2018-06-17 mjldent
  5. [GetPortalCommentsPageByObjectIdResponse(id=2053188, encodeId=9a7420531882c, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat May 12 03:57:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926848, encodeId=35d71926848d2, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Mon Jun 11 04:57:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688290, encodeId=c1f9168829076, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Mon Apr 02 21:57:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747265, encodeId=34f01e4726537, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 17 23:57:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724441, encodeId=ebc41e2444183, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Sep 15 20:57:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554357, encodeId=5b39155435e20, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Wed Sep 06 02:57:00 CST 2017, time=2017-09-06, status=1, ipAttribution=)]
    2017-09-15 feifers
  6. [GetPortalCommentsPageByObjectIdResponse(id=2053188, encodeId=9a7420531882c, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat May 12 03:57:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926848, encodeId=35d71926848d2, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Mon Jun 11 04:57:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688290, encodeId=c1f9168829076, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Mon Apr 02 21:57:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747265, encodeId=34f01e4726537, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 17 23:57:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724441, encodeId=ebc41e2444183, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Sep 15 20:57:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554357, encodeId=5b39155435e20, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Wed Sep 06 02:57:00 CST 2017, time=2017-09-06, status=1, ipAttribution=)]

相关资讯

Nature&STM:黎明前的黑暗?新型长效艾滋病疗法

斯克利普斯研究所近期在Nature上发表最新研究成果,他们报道了一种新型分子eCD4-Ig,有望在无需每日服用抗逆转病毒药物的情况下控制HIV。相比较已知的广谱的HIV抗体,这一分子能更为广泛地攻击HIV病毒株,且效果更佳。此外在40周的研究期间该分子还安全保护了猴子免受了一种HIV类似病毒的感染。 美国国家过敏及传染病研究所(NIAID)主任Anthony S Fauci博士评论这一工作

Baidu
map
Baidu
map
Baidu
map